Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy

1. The sex does not limit, age:18-70 years old ;
2. The patients have inoperable advanced hepatoma without serious disorder in liver and renal, tumor occupation\< 70 %;
3. The patients have failure in surgical intervention or resection operation recidivist;
4. Hepatic function Child-pugh A、B;
5. All the cases have the definite final diagnosis of imageology results such as MRI、CT 、B ultrasonic or cytology results ;
6. The patient's prediction of live time>6 months, who can tolerant of TACE and has quality of life ECOG score\<3;
7. The patients participate the clinical trial voluntarily and have already signed informed consent.

Exclusion Criteria:

1. Main portal vein was obstructed completely;
2. The occupation of tumour are 70 % or more than 70 % in the whole liver;
3. The patient has recepted TACE or other antineoplaston;
4. After carcinosectomy the patient has the prophylactic;
5. The patient is with renal inadequacy: Cr≥133 umol/L
6. Severe cardiovascular disease;
7. The patient is with other diseases to influence the proposal;
8. All over the body generally have metabasis or be with other malignant neoplastic disease;
9. In the process of participation of other medicinal trial;
10. Gravidity, lactation ,hypersensitiveness constitution or have already known adverse reaction or taboo.